Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 15/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 14/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 14/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24246865 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL18609539 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL20417319 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL24435761 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL25754972 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL22224479 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL19375748 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL23745311 | 0.96 | GNAO1 (0.43) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL22224480 | 0.96 | GNAO1 (0.42) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL23059321 | 0.94 | GNAO1 (0.41) | GNAO1GNAI3GNAI1EPHX1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
| US-10358453-B2 | Antiviral compounds | ALIOS BIOPHARMA, INC. (US) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | GNAO1 1602/4885GNAI3 353/4885GNAI1 202/4885 |
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | GNAO1 2255/4885GNAI3 553/4885GNAI1 343/4885 |
| US-10358453-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | GNAO1 2856/4885GNAI3 963/4885GNAI1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.